Migraine is a debilitating illness and a major cause of disability in the world. It is highly prevalent, especially among women. Vitamin supplementation is a potential therapeutic option for migraines that remains largely under-explored. Several studies have shown that people with migraine tend to have higher arterial stiffness than people without migraine. Vitamin K2 deficiency is an important mediator of arterial stiffness and calcification due to decreased carboxylation of matrix Gla protein (MGP). Supplementation reverses these changes and improves vascular health in patients with end stage renal disease according to previous studies. Therefore, vitamin K2 supplementation could serve a potential role in migraine patients. The purpose of the study is to test the effect of vitamin K2 on decreasing the frequency of migraine attacks and decreasing arterial stiffness. The population will be recruited from the neurology clinic at LAU Medical Center-Rizk Hospital and will constitute of adult patients. They will be randomized to receive either the supplement of vitamin K2 or a placebo for the duration of 6 months. Laboratory tests and arterial stiffness measurements will be done at the beginning, middle, and at the end of the study for comparison.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
160
Vitamin K2 (MK7) 360 mcg/day orally once daily for 6 months
Placebo pills will be administered orally once daily for 6 months
Lebanese American University Medical Center - Rizk Hospital
Beirut, Beyrouth, Lebanon
RECRUITINGChanges of monthly migraine days
Effect of Vitamin K2 supplementation on the changes from baseline in monthly migraine days as compared to placebo. This will be assessed clinically using a questionnaire to be administered at the start, monthly, and at the end of the study (6 months) about frequency and number of migraine days per month.
Time frame: 6 months
Changes from baseline in the headache impact score (HIT-6) as compared to placebo.
Time frame: 6 months
Changes from baseline in monthly severe migraine days.
Changes from baseline in monthly severe migraine days as defined by a visual analogue scale rating above 7, as compared to placebo.
Time frame: 6 months
Changes from baseline on the modified migraine disability assessment (MIDAS) score as compared to placebo.
Time frame: 6 months
Changes from baseline on the modified migraine physical function impact diary (MPFID) as compared to placebo.
Time frame: 6 months
Changes from baseline on the quality of life as measure by the EuroQoL compared to placebo.
Time frame: 6 months
Changes from baseline of arterial stiffness level.
Changes of arterial stiffness level assessed by measuring the cfPWV using Complior Analyze.
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.